efeb2328-6a31-4340-a086-c431a44348e1
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- age_years
- 84.9993155373032
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- MYC_TARGETS_V2+0.510
- OXIDATIVE_PHOSPHORYLATION+0.330
- REACTIVE_OXYGEN_SPECIES_PATHWAY+0.310
- PANCREAS_BETA_CELLS+0.280
- E2F_TARGETS+0.260
- DNA_REPAIR+0.250
- MYC_TARGETS_V1+0.250
- WNT_BETA_CATENIN_SIGNALING+0.250
- ADIPOGENESIS+0.230
- COAGULATION+0.190
Top 10 suppressed
- INTERFERON_ALPHA_RESPONSE-0.390
- INTERFERON_GAMMA_RESPONSE-0.330
- TNFA_SIGNALING_VIA_NFKB-0.330
- PROTEIN_SECRETION-0.220
- MITOTIC_SPINDLE-0.210
- MTORC1_SIGNALING-0.190
- HYPOXIA-0.170
- APOPTOSIS-0.150
- KRAS_SIGNALING_UP-0.120
- ANDROGEN_RESPONSE-0.100
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | d22c9285-50cf-4724-9f81-606fb54c00fc | — | — | 0.813 |
| 2 | d7856acd-b750-4d86-988f-371045e74768 | — | — | 0.793 |
| 3 | TCGA-E2-A2P5-01A-11R-A19W-07 | — | B | 0.787 |
| 4 | MNG154 | — | — | 0.726 |
| 5 | DRR168602 | — | — | 0.721 |
| 6 | MNG581 | — | — | 0.710 |
| 7 | TCGA-AC-A62V-01A-11R-A31O-07 | — | B | 0.709 |
| 8 | 87930a6f-c400-4ef6-93b2-d01baba20d8e | — | — | 0.697 |
| 9 | SRR12475158 | — | — | 0.696 |
| 10 | a9e8b311-dfde-4c34-80a2-5e64f94c596b | — | — | 0.692 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 26 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| MYC_TARGETS_V2 | 0.510 | Idelalisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.330 | Remibrutinib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.310 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.280 | Cobimetinib | — uncovered |
| E2F_TARGETS | 0.260 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.250 | Idelalisib | — uncovered |
| MYC_TARGETS_V1 | 0.250 | Inavolisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.250 | Inavolisib | — uncovered |
| ADIPOGENESIS | 0.230 | Inavolisib | — uncovered |
| COAGULATION | 0.190 | Binimetinib | — uncovered |
| FATTY_ACID_METABOLISM | 0.160 | Inavolisib | — uncovered |
| BILE_ACID_METABOLISM | 0.130 | Inavolisib | — uncovered |
| APICAL_JUNCTION | 0.120 | Inavolisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.110 | Inavolisib | — uncovered |
| UV_RESPONSE_UP | 0.110 | Idelalisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.100 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.090 | Inavolisib | — uncovered |
| KRAS_SIGNALING_DN | 0.090 | Remibrutinib | — uncovered |
| MYOGENESIS | 0.090 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.080 | Remibrutinib | — uncovered |